573759-00-9 Usage
Uses
Used in Pharmaceutical Industry:
4-NITRO-2-(TRIFLUOROMETHYL)BENZO[D]OXAZOLE is used as a chemical intermediate for the synthesis of various organic compounds, particularly in the development of new pharmaceuticals. Its trifluoromethyl group contributes to improving the biological activity and metabolic stability of drug candidates, making it an essential component in drug discovery and design.
Used in Agrochemical Industry:
In the agrochemical sector, 4-NITRO-2-(TRIFLUOROMETHYL)BENZO[D]OXAZOLE serves as an intermediate in the synthesis of compounds used in the development of pesticides and other agrochemical products. Its unique reactivity and properties allow for the creation of effective and targeted agrochemicals.
Overall, 4-NITRO-2-(TRIFLUOROMETHYL)BENZO[D]OXAZOLE plays a significant role in the field of organic chemistry, with its applications spanning across different industries, primarily pharmaceutical and agrochemical, for the synthesis and development of innovative and effective compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 573759-00-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,7,3,7,5 and 9 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 573759-00:
(8*5)+(7*7)+(6*3)+(5*7)+(4*5)+(3*9)+(2*0)+(1*0)=189
189 % 10 = 9
So 573759-00-9 is a valid CAS Registry Number.
573759-00-9Relevant academic research and scientific papers
METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF
-
, (2008/06/13)
Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
-
, (2008/06/13)
Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
